WINSTON-SALEM, N.C. — Biopharmaceutical firm Targacept (Nasdaq: TRGT), which went public in April, reported Thursday a $5.2 million loss for the first quarter of this year.

Targacept, which is developing drugs for treatment of central nervous system disorders and diseases, said it generated revenues of $606,000.

Targacept raised more than $40 million when it went public.